Validation of the breast cancer Analysis Protocol Packages (APPs) for the determination of estrogen and progesterone receptors (ER, PR), human epidermal growth factor recep- tor 2 (HER2) and proliferation index (Ki67) in breast cancer

Rintasyöpä on naisten yleisin syöpä maailmassa. Sillä on merkittävä vaikutus kansanterveyteen sekä yhteiskuntaan ja tämän vuoksi sitä on tutkittu laajasti jo pitkään. Tämän opinnäytetyön tarkoituksena on validoida kaupallisen VIS (Visiopharm A/S) kuva-analyysiohjelmiston analyysiprotokollatpaketit (...

Full description

Bibliographic Details
Main Author: Heikinmäki, Nella
Other Authors: Matemaattis-luonnontieteellinen tiedekunta, Faculty of Sciences, Bio- ja ympäristötieteiden laitos, Department of Biological and Environmental Science, Jyväskylän yliopisto, University of Jyväskylä
Format: Master's thesis
Language:eng
Published: 2022
Subjects:
Online Access: https://jyx.jyu.fi/handle/123456789/81866
_version_ 1828193051128889344
author Heikinmäki, Nella
author2 Matemaattis-luonnontieteellinen tiedekunta Faculty of Sciences Bio- ja ympäristötieteiden laitos Department of Biological and Environmental Science Jyväskylän yliopisto University of Jyväskylä
author_facet Heikinmäki, Nella Matemaattis-luonnontieteellinen tiedekunta Faculty of Sciences Bio- ja ympäristötieteiden laitos Department of Biological and Environmental Science Jyväskylän yliopisto University of Jyväskylä Heikinmäki, Nella Matemaattis-luonnontieteellinen tiedekunta Faculty of Sciences Bio- ja ympäristötieteiden laitos Department of Biological and Environmental Science Jyväskylän yliopisto University of Jyväskylä
author_sort Heikinmäki, Nella
datasource_str_mv jyx
description Rintasyöpä on naisten yleisin syöpä maailmassa. Sillä on merkittävä vaikutus kansanterveyteen sekä yhteiskuntaan ja tämän vuoksi sitä on tutkittu laajasti jo pitkään. Tämän opinnäytetyön tarkoituksena on validoida kaupallisen VIS (Visiopharm A/S) kuva-analyysiohjelmiston analyysiprotokollatpaketit (APP:t) käytettäväksi Seinäjoen keskussairaalan patologian osastolla. APP:ja käytetään rintasyövän ennustetekijöiden, estrogeenireseptorin (ER APP), progesteronireseptorin (PR APP), proliferaa-tioasteen (Ki67 APP) sekä ihmisen epidermaalisen kasvutekijäreseptori 2:n (HER2 APP), määrittämiseen. Validaatio tehtiin vertaamalla APP:ien määrittämää analyysitulosta patologin antamaan tulokseen yhteensä 67 tapauksesta. ER:n tapauksessa 20, PR:n tapauksessa 28 ja Ki67 tapauksessa vain 14 tapauksen osalta APP:ien analyysitulokset olivat hyviä, eli erosivat korkeintaan +/- 2 % patologin antamista tuloksista. HER2 näytteiden osalta kuva-analyysiohjelmisto ei tunnistanut statuksia 0 ja 2 kunnolla ja antoi useimmiten tulokseksi 1 tai 3. Tulosten perusteella voidaan todeta, ettei ohjelmistoa voida ottaa kliiniseen diagnostiseen käyttöön sellaisenaan. Sitä voidaan kuitenkin käyttää diagnostiikkaa tukevana välineenä, mikäli se katsotaan ajankäytöllisesti järkeväksi. Yli puolessa tutkimuksen tapauksista kuva- analyysiohjelmistolla kesti yli 40 minuuttia analysoida yksi tapaus. Breast cancer is the most common cancer among women worldwide. It has a signif- icant effect on the public health and thus it is widely studied and many prognostic and predictive factors have been identified. They are used to optimize the treatment for the patient. Aim of this Thesis work was to validate analysis protocol packages (APPs) in commercial digital image analysis software VIS by Visiopharm. Validation was done for the determination of prognostic factors for clinical use in the pathol- ogy department of Seinäjoki Central Hospital. The validation was done to estrogen receptor (ER APP), progesterone receptor (PR APP), proliferation index Ki67 (Ki67 APP) and human epidermal growth factor receptor 2 (HER2 APP) from 67 clinical cases by comparing the results the software analysis gave to the ones the pathologists had given. In ER 20, in PR 28 and in Ki67 only 14 cases were determined to have a result that differs maximum of +/- 2 % from the result given by pathologist. In HER2 the software analysis did not recognize statuses 0 and 2 as often as 1 and 3. The validation shows that the software cannot be taken into use for clinical diagnostics. However, the software can be used as a supportive tool in clinical diagnostics, if it is seen beneficial considering its time consumption, which was over 40 minutes in over half of the cases.
first_indexed 2024-09-11T08:50:30Z
format Pro gradu
fullrecord [{"key": "dc.contributor.advisor", "value": "Luhtala, Satu", "language": "", "element": "contributor", "qualifier": "advisor", "schema": "dc"}, {"key": "dc.contributor.advisor", "value": "Kuopio, Teijo", "language": "", "element": "contributor", "qualifier": "advisor", "schema": "dc"}, {"key": "dc.contributor.author", "value": "Heikinm\u00e4ki, Nella", "language": "", "element": "contributor", "qualifier": "author", "schema": "dc"}, {"key": "dc.date.accessioned", "value": "2022-06-20T05:28:02Z", "language": null, "element": "date", "qualifier": "accessioned", "schema": "dc"}, {"key": "dc.date.available", "value": "2022-06-20T05:28:02Z", "language": null, "element": "date", "qualifier": "available", "schema": "dc"}, {"key": "dc.date.issued", "value": "2022", "language": "", "element": "date", "qualifier": "issued", "schema": "dc"}, {"key": "dc.identifier.uri", "value": "https://jyx.jyu.fi/handle/123456789/81866", "language": null, "element": "identifier", "qualifier": "uri", "schema": "dc"}, {"key": "dc.description.abstract", "value": "Rintasy\u00f6p\u00e4 on naisten yleisin sy\u00f6p\u00e4 maailmassa. Sill\u00e4 on merkitt\u00e4v\u00e4 vaikutus kansanterveyteen sek\u00e4 yhteiskuntaan ja t\u00e4m\u00e4n vuoksi sit\u00e4 on tutkittu laajasti jo pitk\u00e4\u00e4n. T\u00e4m\u00e4n opinn\u00e4ytety\u00f6n tarkoituksena on validoida kaupallisen VIS (Visiopharm A/S) kuva-analyysiohjelmiston analyysiprotokollatpaketit (APP:t) k\u00e4ytett\u00e4v\u00e4ksi Sein\u00e4joen keskussairaalan patologian osastolla. APP:ja k\u00e4ytet\u00e4\u00e4n rintasy\u00f6v\u00e4n ennustetekij\u00f6iden, estrogeenireseptorin (ER APP), progesteronireseptorin (PR APP), proliferaa-tioasteen (Ki67 APP) sek\u00e4 ihmisen epidermaalisen kasvutekij\u00e4reseptori 2:n (HER2 APP), m\u00e4\u00e4ritt\u00e4miseen. Validaatio tehtiin vertaamalla APP:ien m\u00e4\u00e4ritt\u00e4m\u00e4\u00e4 analyysitulosta patologin antamaan tulokseen yhteens\u00e4 67 tapauksesta. ER:n tapauksessa 20, PR:n tapauksessa 28 ja Ki67 tapauksessa vain 14 tapauksen osalta APP:ien analyysitulokset olivat hyvi\u00e4, eli erosivat korkeintaan +/- 2 % patologin antamista tuloksista. HER2 n\u00e4ytteiden osalta kuva-analyysiohjelmisto ei tunnistanut statuksia 0 ja 2 kunnolla ja antoi useimmiten tulokseksi 1 tai 3. Tulosten perusteella voidaan todeta, ettei ohjelmistoa voida ottaa kliiniseen diagnostiseen k\u00e4ytt\u00f6\u00f6n sellaisenaan. Sit\u00e4 voidaan kuitenkin k\u00e4ytt\u00e4\u00e4 diagnostiikkaa tukevana v\u00e4lineen\u00e4, mik\u00e4li se katsotaan ajank\u00e4yt\u00f6llisesti j\u00e4rkev\u00e4ksi. Yli puolessa tutkimuksen tapauksista kuva-\nanalyysiohjelmistolla kesti yli 40 minuuttia analysoida yksi tapaus.", "language": "fi", "element": "description", "qualifier": "abstract", "schema": "dc"}, {"key": "dc.description.abstract", "value": "Breast cancer is the most common cancer among women worldwide. It has a signif- icant effect on the public health and thus it is widely studied and many prognostic and predictive factors have been identified. They are used to optimize the treatment for the patient. Aim of this Thesis work was to validate analysis protocol packages (APPs) in commercial digital image analysis software VIS by Visiopharm. Validation was done for the determination of prognostic factors for clinical use in the pathol- ogy department of Sein\u00e4joki Central Hospital. The validation was done to estrogen receptor (ER APP), progesterone receptor (PR APP), proliferation index Ki67 (Ki67 APP) and human epidermal growth factor receptor 2 (HER2 APP) from 67 clinical cases by comparing the results the software analysis gave to the ones the pathologists had given. In ER 20, in PR 28 and in Ki67 only 14 cases were determined to have a result that differs maximum of +/- 2 % from the result given by pathologist. In HER2 the software analysis did not recognize statuses 0 and 2 as often as 1 and 3. The validation shows that the software cannot be taken into use for clinical diagnostics. However, the software can be used as a supportive tool in clinical diagnostics, if it is seen beneficial considering its time consumption, which was over 40 minutes\nin over half of the cases.", "language": "en", "element": "description", "qualifier": "abstract", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Submitted by Miia Hakanen (mihakane@jyu.fi) on 2022-06-20T05:28:02Z\nNo. of bitstreams: 0", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.description.provenance", "value": "Made available in DSpace on 2022-06-20T05:28:02Z (GMT). No. of bitstreams: 0\n Previous issue date: 2022", "language": "en", "element": "description", "qualifier": "provenance", "schema": "dc"}, {"key": "dc.format.extent", "value": "55", "language": "", "element": "format", "qualifier": "extent", "schema": "dc"}, {"key": "dc.format.mimetype", "value": "application/pdf", "language": null, "element": "format", "qualifier": "mimetype", "schema": "dc"}, {"key": "dc.language.iso", "value": "eng", "language": null, "element": "language", "qualifier": "iso", "schema": "dc"}, {"key": "dc.rights", "value": "In Copyright", "language": "en", "element": "rights", "qualifier": null, "schema": "dc"}, {"key": "dc.subject.other", "value": "digital pathology", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "digital image analysis", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "ER", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "PR", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "Ki67", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "HER2", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.subject.other", "value": "c-erbB2", "language": "", "element": "subject", "qualifier": "other", "schema": "dc"}, {"key": "dc.title", "value": "Validation of the breast cancer Analysis Protocol Packages (APPs) for the determination of estrogen and progesterone receptors (ER, PR), human epidermal growth factor recep- tor 2 (HER2) and proliferation index (Ki67) in breast cancer", "language": "", "element": "title", "qualifier": null, "schema": "dc"}, {"key": "dc.type", "value": "master thesis", "language": null, "element": "type", "qualifier": null, "schema": "dc"}, {"key": "dc.identifier.urn", "value": "URN:NBN:fi:jyu-202206203475", "language": "", "element": "identifier", "qualifier": "urn", "schema": "dc"}, {"key": "dc.type.ontasot", "value": "Pro gradu -tutkielma", "language": "fi", "element": "type", "qualifier": "ontasot", "schema": "dc"}, {"key": "dc.type.ontasot", "value": "Master\u2019s thesis", "language": "en", "element": "type", "qualifier": "ontasot", "schema": "dc"}, {"key": "dc.contributor.faculty", "value": "Matemaattis-luonnontieteellinen tiedekunta", "language": "fi", "element": "contributor", "qualifier": "faculty", "schema": "dc"}, {"key": "dc.contributor.faculty", "value": "Faculty of Sciences", "language": "en", "element": "contributor", "qualifier": "faculty", "schema": "dc"}, {"key": "dc.contributor.department", "value": "Bio- ja ymp\u00e4rist\u00f6tieteiden laitos", "language": "fi", "element": "contributor", "qualifier": "department", "schema": "dc"}, {"key": "dc.contributor.department", "value": "Department of Biological and Environmental Science", "language": "en", "element": "contributor", "qualifier": "department", "schema": "dc"}, {"key": "dc.contributor.organization", "value": "Jyv\u00e4skyl\u00e4n yliopisto", "language": "fi", "element": "contributor", "qualifier": "organization", "schema": "dc"}, {"key": "dc.contributor.organization", "value": "University of Jyv\u00e4skyl\u00e4", "language": "en", "element": "contributor", "qualifier": "organization", "schema": "dc"}, {"key": "dc.subject.discipline", "value": "Solu- ja molekyylibiologia", "language": "fi", "element": "subject", "qualifier": "discipline", "schema": "dc"}, {"key": "dc.subject.discipline", "value": "Cell and molecular biology", "language": "en", "element": "subject", "qualifier": "discipline", "schema": "dc"}, {"key": "yvv.contractresearch.collaborator", "value": "public", "language": "", "element": "contractresearch", "qualifier": "collaborator", "schema": "yvv"}, {"key": "yvv.contractresearch.funding", "value": "0", "language": "", "element": "contractresearch", "qualifier": "funding", "schema": "yvv"}, {"key": "yvv.contractresearch.initiative", "value": "student", "language": "", "element": "contractresearch", "qualifier": "initiative", "schema": "yvv"}, {"key": "dc.type.coar", "value": "http://purl.org/coar/resource_type/c_bdcc", "language": null, "element": "type", "qualifier": "coar", "schema": "dc"}, {"key": "dc.rights.accesslevel", "value": "restrictedAccess", "language": null, "element": "rights", "qualifier": "accesslevel", "schema": "dc"}, {"key": "dc.type.publication", "value": "masterThesis", "language": null, "element": "type", "qualifier": "publication", "schema": "dc"}, {"key": "dc.subject.oppiainekoodi", "value": "4013", "language": "", "element": "subject", "qualifier": "oppiainekoodi", "schema": "dc"}, {"key": "dc.subject.yso", "value": "rintasy\u00f6p\u00e4", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "sy\u00f6p\u00e4taudit", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "breast cancer", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.subject.yso", "value": "cancerous diseases", "language": null, "element": "subject", "qualifier": "yso", "schema": "dc"}, {"key": "dc.format.content", "value": "fulltext", "language": null, "element": "format", "qualifier": "content", "schema": "dc"}, {"key": "dc.rights.url", "value": "https://rightsstatements.org/page/InC/1.0/", "language": null, "element": "rights", "qualifier": "url", "schema": "dc"}, {"key": "dc.rights.accessrights", "value": "The author has not given permission to make the work publicly available electronically. Therefore the material can be read only at the archival workstation at Jyv\u00e4skyl\u00e4 University Library (https://kirjasto.jyu.fi/collections/archival-workstation).", "language": "en", "element": "rights", "qualifier": "accessrights", "schema": "dc"}, {"key": "dc.rights.accessrights", "value": "Tekij\u00e4 ei ole antanut lupaa avoimeen julkaisuun, joten aineisto on luettavissa vain Jyv\u00e4skyl\u00e4n yliopiston kirjaston arkistoty\u00f6semalta. Ks. https://kirjasto.jyu.fi/kokoelmat/arkistotyoasema..", "language": "fi", "element": "rights", "qualifier": "accessrights", "schema": "dc"}, {"key": "dc.type.okm", "value": "G2", "language": null, "element": "type", "qualifier": "okm", "schema": "dc"}]
id jyx.123456789_81866
language eng
last_indexed 2025-03-31T20:03:07Z
main_date 2022-01-01T00:00:00Z
main_date_str 2022
publishDate 2022
record_format qdc
source_str_mv jyx
spellingShingle Heikinmäki, Nella Validation of the breast cancer Analysis Protocol Packages (APPs) for the determination of estrogen and progesterone receptors (ER, PR), human epidermal growth factor recep- tor 2 (HER2) and proliferation index (Ki67) in breast cancer digital pathology digital image analysis ER PR Ki67 HER2 c-erbB2 Solu- ja molekyylibiologia Cell and molecular biology 4013 rintasyöpä syöpätaudit breast cancer cancerous diseases
title Validation of the breast cancer Analysis Protocol Packages (APPs) for the determination of estrogen and progesterone receptors (ER, PR), human epidermal growth factor recep- tor 2 (HER2) and proliferation index (Ki67) in breast cancer
title_full Validation of the breast cancer Analysis Protocol Packages (APPs) for the determination of estrogen and progesterone receptors (ER, PR), human epidermal growth factor recep- tor 2 (HER2) and proliferation index (Ki67) in breast cancer
title_fullStr Validation of the breast cancer Analysis Protocol Packages (APPs) for the determination of estrogen and progesterone receptors (ER, PR), human epidermal growth factor recep- tor 2 (HER2) and proliferation index (Ki67) in breast cancer Validation of the breast cancer Analysis Protocol Packages (APPs) for the determination of estrogen and progesterone receptors (ER, PR), human epidermal growth factor recep- tor 2 (HER2) and proliferation index (Ki67) in breast cancer
title_full_unstemmed Validation of the breast cancer Analysis Protocol Packages (APPs) for the determination of estrogen and progesterone receptors (ER, PR), human epidermal growth factor recep- tor 2 (HER2) and proliferation index (Ki67) in breast cancer Validation of the breast cancer Analysis Protocol Packages (APPs) for the determination of estrogen and progesterone receptors (ER, PR), human epidermal growth factor recep- tor 2 (HER2) and proliferation index (Ki67) in breast cancer
title_short Validation of the breast cancer Analysis Protocol Packages (APPs) for the determination of estrogen and progesterone receptors (ER, PR), human epidermal growth factor recep- tor 2 (HER2) and proliferation index (Ki67) in breast cancer
title_sort validation of the breast cancer analysis protocol packages apps for the determination of estrogen and progesterone receptors er pr human epidermal growth factor recep tor 2 her2 and proliferation index ki67 in breast cancer
title_txtP Validation of the breast cancer Analysis Protocol Packages (APPs) for the determination of estrogen and progesterone receptors (ER, PR), human epidermal growth factor recep- tor 2 (HER2) and proliferation index (Ki67) in breast cancer
topic digital pathology digital image analysis ER PR Ki67 HER2 c-erbB2 Solu- ja molekyylibiologia Cell and molecular biology 4013 rintasyöpä syöpätaudit breast cancer cancerous diseases
topic_facet 4013 Cell and molecular biology ER HER2 Ki67 PR Solu- ja molekyylibiologia breast cancer c-erbB2 cancerous diseases digital image analysis digital pathology rintasyöpä syöpätaudit
url https://jyx.jyu.fi/handle/123456789/81866 http://www.urn.fi/URN:NBN:fi:jyu-202206203475
work_keys_str_mv AT heikinmäkinella validationofthebreastcanceranalysisprotocolpackagesappsforthedeterminationofestr